These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23435876)

  • 21. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
    Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
    J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.
    Atmaca A; Al-Batran SE; Werner D; Pauligk C; Güner T; Koepke A; Bernhard H; Wenzel T; Banat AG; Brueck P; Caca K; Prasnikar N; Kullmann F; Günther Derigs H; Koenigsmann M; Dingeldein G; Neuhaus T; Jäger E
    Br J Cancer; 2013 Feb; 108(2):265-70. PubMed ID: 23329236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
    Leighl NB; Laurie SA; Chen XE; Ellis P; Shepherd FA; Knox JJ; Goss G; Burkes RL; Pond GR; Dick C; Yen Y; Zwiebel JA; Moore MJ
    J Thorac Oncol; 2009 Sep; 4(9):1163-9. PubMed ID: 19704337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
    Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
    Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
    Mok TS; Ho S; Chan G; Ho WM; Wong H; Chan AT; Yeo W; Yim AP; Chak K; Lee Y; Lam KC
    J Thorac Oncol; 2007 Sep; 2(9):838-44. PubMed ID: 17805062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer.
    Cho SH; Go SI; Lee GW; Kang JH; Kim HG; Kim SH; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS
    Lung Cancer; 2010 Jul; 69(1):94-8. PubMed ID: 19796840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
    Mattson K; Vansteenkiste J; Stupp R; Bargetzi M; Saarinen A; Jekunen A; Fillet G; Teixeira M; Gatzemeier U; Olivares R; Soussan-Lazard K; Bérille J
    Anticancer Drugs; 2000 Jan; 11(1):7-13. PubMed ID: 10757557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
    Pérol M; Léna H; Thomas P; Robinet G; Fournel P; Coste E; Belleguic C; Le Caer H; Blanchon F; Vergnenègre A; Vernejoux JM; Schuller-Lebeau MP; Pham E
    Ann Oncol; 2002 May; 13(5):742-7. PubMed ID: 12075743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
    Moulder S; Dhillon N; Ng C; Hong D; Wheler J; Naing A; Tse S; La Paglia A; Dorr R; Hersh E; Boytim M; Kurzrock R
    Invest New Drugs; 2010 Oct; 28(5):634-40. PubMed ID: 19499186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
    Gelmon KA; Stewart D; Chi KN; Chia S; Cripps C; Huan S; Janke S; Ayers D; Fry D; Shabbits JA; Walsh W; McIntosh L; Seymour LK
    Ann Oncol; 2004 Jul; 15(7):1115-22. PubMed ID: 15205207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
    Sangha R; Davies AM; Lara PN; Mack PC; Beckett LA; Hesketh PJ; Lau D; Li T; Perkins N; Gandara DR
    J Thorac Oncol; 2011 Dec; 6(12):2112-9. PubMed ID: 21892109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
    Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients.
    Ohe Y; Niho S; Kakinuma R; Kubota K; Matsumoto T; Ohmatsu H; Goto K; Kunitoh H; Saijo N; Nishiwaki Y
    Jpn J Clin Oncol; 2001 Mar; 31(3):100-6. PubMed ID: 11336320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
    Miller AA; Wang XF; Gu L; Hoffman P; Khatri J; Dunphy F; Edelman MJ; Bolger M; Vokes EE; Green MR;
    J Thorac Oncol; 2008 Oct; 3(10):1159-65. PubMed ID: 18827613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.